217 related articles for article (PubMed ID: 22389383)
1. Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway.
Chen H; Sun Y; Wu C; Magyar CE; Li X; Cheng L; Yao JL; Shen S; Osunkoya AO; Liang C; Huang J
Endocr Relat Cancer; 2012 Jun; 19(3):321-31. PubMed ID: 22389383
[TBL] [Abstract][Full Text] [Related]
2. p53 Mutation Directs AURKA Overexpression via miR-25 and FBXW7 in Prostatic Small Cell Neuroendocrine Carcinoma.
Li Z; Sun Y; Chen X; Squires J; Nowroozizadeh B; Liang C; Huang J
Mol Cancer Res; 2015 Mar; 13(3):584-91. PubMed ID: 25512615
[TBL] [Abstract][Full Text] [Related]
3. Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation.
Lipianskaya J; Cohen A; Chen CJ; Hsia E; Squires J; Li Z; Zhang Y; Li W; Chen X; Xu H; Huang J
Asian J Androl; 2014; 16(4):541-4. PubMed ID: 24589459
[TBL] [Abstract][Full Text] [Related]
4. PC3 is a cell line characteristic of prostatic small cell carcinoma.
Tai S; Sun Y; Squires JM; Zhang H; Oh WK; Liang CZ; Huang J
Prostate; 2011 Nov; 71(15):1668-79. PubMed ID: 21432867
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
Kaur H; Samarska I; Lu J; Faisal F; Maughan BL; Murali S; Asrani K; Alshalalfa M; Antonarakis ES; Epstein JI; Joshu CE; Schaeffer EM; Mosquera JM; Lotan TL
Prostate; 2020 Sep; 80(12):1012-1023. PubMed ID: 32649013
[TBL] [Abstract][Full Text] [Related]
6. Neuroendocrine differentiation of prostate cancer.
Li Z; Chen CJ; Wang JK; Hsia E; Li W; Squires J; Sun Y; Huang J
Asian J Androl; 2013 May; 15(3):328-32. PubMed ID: 23503426
[No Abstract] [Full Text] [Related]
7. Neuroendocrine cells of prostate cancer: biologic functions and molecular mechanisms.
Huang YH; Zhang YQ; Huang JT
Asian J Androl; 2019; 21(3):291-295. PubMed ID: 30924452
[TBL] [Abstract][Full Text] [Related]
8. Telomere lengths differ significantly between small-cell neuroendocrine prostate carcinoma and adenocarcinoma of the prostate.
Heaphy CM; Haffner MC; Graham MK; Lim D; Davis C; Corey E; Epstein JI; Eisenberger MA; Wang H; De Marzo AM; Meeker AK; Lotan TL
Hum Pathol; 2020 Jul; 101():70-79. PubMed ID: 32389660
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological and genetic analyses of small cell neuroendocrine carcinoma of the prostate: Histological features for accurate diagnosis and toward future novel therapies.
Ida A; Okubo Y; Kasajima R; Washimi K; Sato S; Yoshioka E; Osaka K; Suzuki T; Yamamoto Y; Yokose T; Kishida T; Miyagi Y
Pathol Res Pract; 2022 Jan; 229():153731. PubMed ID: 34952423
[TBL] [Abstract][Full Text] [Related]
10. Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate.
Hansel DE; Nakayama M; Luo J; Abukhdeir AM; Park BH; Bieberich CJ; Hicks JL; Eisenberger M; Nelson WG; Mostwin JL; De Marzo AM
Prostate; 2009 May; 69(6):603-9. PubMed ID: 19125417
[TBL] [Abstract][Full Text] [Related]
11. Oncofetal protein glypican-3 is a biomarker and critical regulator of function for neuroendocrine cells in prostate cancer.
Butler W; Xu L; Zhou Y; Cheng Q; Hauck JS; He Y; Marek R; Hartman Z; Cheng L; Yang Q; Wang ME; Chen M; Zhang H; Armstrong AJ; Huang J
J Pathol; 2023 May; 260(1):43-55. PubMed ID: 36752189
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis incidence and protein expression of p53, TGF-beta receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate.
Zeng L; Rowland RG; Lele SM; Kyprianou N
Hum Pathol; 2004 Mar; 35(3):290-7. PubMed ID: 15017584
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer.
Huang J; Yao JL; Zhang L; Bourne PA; Quinn AM; di Sant'Agnese PA; Reeder JE
Am J Pathol; 2005 Jun; 166(6):1807-15. PubMed ID: 15920165
[TBL] [Abstract][Full Text] [Related]
14. Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer.
Li Y; He Y; Butler W; Xu L; Chang Y; Lei K; Zhang H; Zhou Y; Gao AC; Zhang Q; Taylor DG; Cheng D; Farber-Katz S; Karam R; Landrith T; Li B; Wu S; Hsuan V; Yang Q; Hu H; Chen X; Flowers M; McCall SJ; Lee JK; Smith BA; Park JW; Goldstein AS; Witte ON; Wang Q; Rettig MB; Armstrong AJ; Cheng Q; Huang J
Sci Transl Med; 2019 Dec; 11(521):. PubMed ID: 31801883
[TBL] [Abstract][Full Text] [Related]
15. [Cancer of the prostate: evaluation of the expression of the mutated protein of the 53 tumor suppressor gene].
Rivera P; Ibacache G; GarcĂa M; Roa I; Orio M
Actas Urol Esp; 1997 Oct; 21(9):822-6. PubMed ID: 9471864
[TBL] [Abstract][Full Text] [Related]
16. Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer.
Evans AJ; Humphrey PA; Belani J; van der Kwast TH; Srigley JR
Am J Surg Pathol; 2006 Jun; 30(6):684-93. PubMed ID: 16723845
[TBL] [Abstract][Full Text] [Related]
17. Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia.
Kwak C; Jin RJ; Lee C; Park MS; Lee SE
BJU Int; 2002 Feb; 89(3):303-9. PubMed ID: 11856116
[TBL] [Abstract][Full Text] [Related]
18. Attenuated response of p53 and p21 in primary cultures of human prostatic epithelial cells exposed to DNA-damaging agents.
Girinsky T; Koumenis C; Graeber TG; Peehl DM; Giaccia AJ
Cancer Res; 1995 Sep; 55(17):3726-31. PubMed ID: 7543816
[TBL] [Abstract][Full Text] [Related]
19. CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers.
Simon RA; di Sant'Agnese PA; Huang LS; Xu H; Yao JL; Yang Q; Liang S; Liu J; Yu R; Cheng L; Oh WK; Palapattu GS; Wei J; Huang J
Hum Pathol; 2009 Feb; 40(2):252-8. PubMed ID: 18835619
[TBL] [Abstract][Full Text] [Related]
20. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma.
Navone NM; Troncoso P; Pisters LL; Goodrow TL; Palmer JL; Nichols WW; von Eschenbach AC; Conti CJ
J Natl Cancer Inst; 1993 Oct; 85(20):1657-69. PubMed ID: 7692074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]